GO:0007271 synaptic transmission, cholinergic: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007271 synaptic transmission, cholinergic describes the vesicular release of acetylcholine from a presynapse, activation of postsynaptic receptors, and the resulting changes in postsynaptic membrane potential and ionic composition.
• Cholinergic transmission is mediated by a conserved molecular machinery including ChAT, VAChT, AChE, nAChRs and mAChRs, and is modulated by proteins such as CASK and FARP.
• Cholinergic signaling dynamically modulates excitatory synaptic transmission in multiple brain regions, including the hippocampus, entorhinal cortex, and parasubiculum.
• Striatal cholinergic interneurons can signal to dopaminergic fibers via synaptic-like axo-axonal transmission, expanding the known roles of cholinergic circuits.
• Cholinergic and adenosinergic systems interact to fine-tune synaptic release, providing multiple entry points for pharmacological and genetic interrogation.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of cholinergic genes in health and disease.
Description
Synaptic transmission, cholinergic (GO:0007271) is a biological process that encompasses the vesicular release of acetylcholine (ACh) from a presynaptic terminal, the activation of postsynaptic receptors, and the downstream effects on the postsynaptic membrane potential and ionic composition. This form of neurotransmission is essential for motor control, autonomic function, learning, memory, and many other physiological processes, and its dysfunction is implicated in neurological and psychiatric disorders. Researchers study cholinergic transmission to understand how neural circuits compute, how drugs modulate synaptic strength, and how disease-associated mutations alter synaptic function. The process is experimentally tractable using electrophysiology, imaging, and genetic tools, and it is increasingly dissected with CRISPR-based models that allow precise perturbation of cholinergic genes.
synaptic transmission, cholinergic At A Glance
| GO ID | GO:0007271 |
|---|---|
| GO term | synaptic transmission, cholinergic |
| Ontology | biological_process |
| Synonym | cholinergic synaptic transmission |
| Definition | The vesicular release of acetylcholine from a presynapse, activation of postsynaptic receptors, and effects on postsynaptic membrane potential and ionic composition. |
| Major function | Fast and modulatory neurotransmission in the central and peripheral nervous systems. |
| Key neurotransmitter | Acetylcholine (ACh). |
| Representative genes | CHAT, SLC18A3 (VAChT), ACHE, CHRNA1-10, CHRNB1-4, CHRND, CHRNE, CHRM1-5. |
| Related diseases | Myasthenia gravis, congenital myasthenic syndromes, Alzheimer disease, Parkinson disease. |
What Is GO:0007271?
According to the Gene Ontology, synaptic transmission, cholinergic (GO:0007271) is the vesicular release of acetylcholine from a presynapse, across a chemical synapse, the subsequent activation of acetylcholine receptors at the postsynapse of a target cell (neuron, muscle, or secretory cell), and the effects of this activation on the postsynaptic membrane potential and ionic composition of the postsynaptic cytosol. This process includes both spontaneous and evoked release of neurotransmitter and all parts of synaptic vesicle exocytosis. Evoked transmission starts with the arrival of an action potential at the presynapse.
Why Is synaptic transmission, cholinergic Important in Cell Biology?
Cholinergic transmission is a fundamental mode of chemical synaptic signaling that controls muscle contraction, autonomic functions, arousal, attention, learning, and memory. Its precise regulation is required for normal circuit operation, and its perturbation contributes to disorders ranging from myasthenia gravis to Alzheimer disease and Parkinson disease. Because cholinergic synapses are accessible and well-characterized, they serve as a paradigm for studying synaptic vesicle cycling, receptor activation, and neuromodulation.
• Controls skeletal muscle contraction at the neuromuscular junction.
• Regulates autonomic functions such as heart rate, glandular secretion, and smooth muscle tone.
• Modulates excitatory synaptic transmission in the hippocampus and entorhinal cortex, influencing learning and memory.
• Shapes striatal dopamine signaling through axo-axonal cholinergic transmission.
• Is a target of drugs used in anesthesia, Alzheimer disease, and myasthenia gravis.
• Provides a model system for studying synaptic vesicle exocytosis and receptor pharmacology.
• Is modulated by steroid hormones such as estrogen, as shown by ovariectomy studies.
• Involves post-synaptic scaffolding proteins like CASK and FARP that organize ACh receptors.
• Interacts with adenosinergic signaling to fine-tune neurotransmitter release.
• Dysfunction is linked to congenital myasthenic syndromes and neurodegenerative disorders.
What Happens During synaptic transmission, cholinergic?
Acetylcholine synthesis and vesicular packaging
In simple terms: The neuron makes acetylcholine and packs it into small bubbles called vesicles.
Cholinergic neurons synthesize acetylcholine (ACh) from choline and acetyl-CoA by the enzyme choline acetyltransferase (ChAT). ACh is then transported into synaptic vesicles by the vesicular acetylcholine transporter (VAChT, encoded by SLC18A3), which uses a proton gradient to concentrate ACh inside vesicles. This packaging step is essential for subsequent quantal release and is a point of regulation by cholinergic and adenosinergic signaling.
Action potential arrival and calcium-triggered vesicle fusion
In simple terms: When an electrical signal reaches the nerve ending, calcium enters and causes the bubbles to fuse with the membrane, releasing acetylcholine.
Evoked cholinergic transmission begins with the arrival of an action potential at the presynaptic terminal, which opens voltage-gated calcium channels and triggers a local rise in intracellular calcium. Calcium binds to synaptotagmin and other fusion machinery, causing synaptic vesicles to fuse with the plasma membrane and release ACh into the synaptic cleft. This process encompasses both spontaneous and evoked release and all parts of synaptic vesicle exocytosis.
Postsynaptic receptor activation
In simple terms: Acetylcholine crosses the gap and binds to receptor proteins on the next cell, changing its electrical state.
Released ACh diffuses across the synaptic cleft and binds to postsynaptic receptors, which are either nicotinic acetylcholine receptors (nAChRs, ligand-gated ion channels) or muscarinic acetylcholine receptors (mAChRs, G-protein-coupled receptors). Activation of nAChRs causes rapid ion flux and depolarization, while mAChR activation triggers slower metabotropic signaling. The precise localization of these receptors is organized by scaffolding proteins such as CASK and FARP, which promote efficient cholinergic transmission.
Termination of signaling by acetylcholinesterase
In simple terms: An enzyme quickly breaks down acetylcholine so the signal stops and the synapse can reset.
Acetylcholinesterase (AChE) hydrolyzes ACh in the synaptic cleft into choline and acetate, terminating the postsynaptic response and allowing choline to be recycled by the presynaptic terminal. This rapid clearance is critical for high-frequency transmission and is the target of cholinesterase inhibitors used clinically.
Modulation of cholinergic transmission
In simple terms: Other signals can turn the strength of acetylcholine signaling up or down.
Cholinergic transmission is modulated by numerous factors, including adenosinergic signaling, steroid hormones, and presynaptic autoreceptors. For example, ovariectomy reduces cholinergic modulation of excitatory synaptic transmission in the rat entorhinal cortex, indicating hormonal regulation. Cholinergic interneurons can also signal to dopaminergic fibers via synaptic-like axo-axonal transmission, illustrating non-canonical modulation of other neurotransmitter systems.
Key Genes Involved in GO:0007271 synaptic transmission, cholinergic
The following genes encode core components and regulators of cholinergic synaptic transmission, and they are frequently studied using genetic and pharmacological approaches.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CHAT | Synthesizes acetylcholine from choline and acetyl-CoA | Marker of cholinergic neurons; target for knockout studies of ACh synthesis |
| SLC18A3 (VAChT) | Packages ACh into synaptic vesicles | Essential for quantal release; knockout reduces cholinergic transmission |
| ACHE | Hydrolyzes ACh to terminate signaling | Target of cholinesterase inhibitors; mutations cause synaptic dysfunction |
| CHRNA1 | Nicotinic ACh receptor subunit (muscle-type) | Mutations cause congenital myasthenic syndromes |
| CHRNB1 | Nicotinic ACh receptor subunit | Required for neuromuscular junction function |
| CHRND | Nicotinic ACh receptor subunit | Associated with congenital myasthenic syndromes |
| CHRNE | Nicotinic ACh receptor subunit | Commonly mutated in congenital myasthenia |
| CHRNA7 | Nicotinic ACh receptor subunit (alpha7) | Implicated in cognitive function and schizophrenia |
| CHRM1 | Muscarinic ACh receptor M1 | Modulates excitatory transmission in cortex and hippocampus |
| CHRM2 | Muscarinic ACh receptor M2 | Presynaptic autoreceptor regulating ACh release |
| CASK | Scaffolding protein at postsynaptic sites | Localizes ACh receptors and promotes cholinergic transmission |
| FARP1 | Scaffolding protein interacting with CASK | Organizes post-synaptic ACh receptors |
| SLC5A7 (CHT1) | High-affinity choline transporter | Rate-limiting for ACh synthesis; regulates transmission |
| SYT1 | Synaptotagmin 1, calcium sensor for vesicle fusion | Required for evoked ACh release |
| SNAP25 | SNARE protein for vesicle fusion | Essential for synaptic vesicle exocytosis |
| STX1A | Syntaxin 1A, SNARE protein | Mediates vesicle-plasma membrane fusion |
| VAMP2 | Vesicle-associated membrane protein 2 | SNARE component for ACh release |
| ADORA1 | Adenosine A1 receptor | Modulates cholinergic and excitatory synaptic release |
How Is synaptic transmission, cholinergic Regulated?
Cholinergic transmission is regulated at multiple levels. Presynaptic M2 muscarinic autoreceptors and adenosine A1 receptors inhibit ACh release, while adenosinergic signaling can also modulate excitatory transmission. Steroid hormones such as estrogen influence cholinergic modulation, as ovariectomy reduces cholinergic effects on excitatory synaptic transmission in the entorhinal cortex. Postsynaptic scaffolding proteins CASK and FARP localize ACh receptors and thereby promote efficient cholinergic transmission. Additionally, cholinergic interneurons can regulate dopamine release through axo-axonal mechanisms.
synaptic transmission, cholinergic and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CHRNE | Congenital myasthenic syndrome | Knock-in mouse with patient mutation; electrophysiology at neuromuscular junction |
| ACHE | Alzheimer disease (symptomatic treatment target) | Knockout or point-mutation cell models to test cholinesterase inhibitors |
| CHRNA7 | Schizophrenia and cognitive deficits | Overexpression or knockout in neuronal cultures; calcium imaging |
| CASK | Cholinergic transmission and synaptic scaffolding | Knockout and knock-in models to study ACh receptor localization |
| CHRM1 | Cortical excitability and epilepsy | Conditional knockout in cortex; slice electrophysiology |
Myasthenia gravis and congenital myasthenic syndromes
Impaired cholinergic transmission at the neuromuscular junction causes muscle weakness in myasthenia gravis and congenital myasthenic syndromes, often due to autoantibodies or mutations in nicotinic ACh receptor subunits such as CHRNA1, CHRNB1, CHRND, and CHRNE. These disorders highlight the clinical importance of precise cholinergic signaling.
Alzheimer disease and cognitive decline
Cholinergic neurons in the basal forebrain degenerate in Alzheimer disease, contributing to memory and attention deficits. Cholinesterase inhibitors that boost cholinergic transmission are used symptomatic treatment, underscoring the link between GO:0007271 and cognition.
Parkinson disease and striatal circuits
Striatal cholinergic interneurons modulate dopaminergic signaling via synaptic-like axo-axonal transmission, and their dysfunction is implicated in Parkinson disease motor symptoms. This interaction provides a rationale for targeting cholinergic pathways in Parkinson disease research.
Epilepsy and cortical excitability
Cholinergic modulation of excitatory synaptic transmission in the hippocampus and parasubiculum influences network excitability, and altered cholinergic tone may contribute to seizure susceptibility. Studying these pathways can inform antiepileptic strategies.
From synaptic transmission, cholinergic-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CHAT abolish ACh synthesis? | CHAT knockout cell line or mouse; LC-MS measurement of ACh |
| How do disease mutations in CHRNE affect receptor function? | Point-mutation knock-in in HEK293 or neuronal cells; patch-clamp |
| Where is VAChT localized in live neurons? | Tagged knock-in of SLC18A3 with fluorescent protein; imaging |
| Does overexpression of CASK enhance cholinergic transmission? | Overexpression in cultured neurons; electrophysiology |
| What is the effect of FARP1 knockout on ACh receptor clustering? | FARP1 knockout cells; immunofluorescence and co-culture |
| Can cholinergic modulation be restored by estrogen? | Ovariectomized rat model with electrophysiology |
How to Study the synaptic transmission, cholinergic Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | Postsynaptic currents and membrane potential | Quantify cholinergic transmission in slices |
| Fluorescence imaging | Vesicle and receptor localization | Study synapse structure and receptor clustering |
| CRISPR knockout | Loss-of-function phenotype | Test necessity of cholinergic genes |
| CRISPR knock-in | Tagged or mutant protein expression | Track localization or model disease mutations |
| Mass spectrometry | Acetylcholine levels | Measure synthesis and release |
| Cholinesterase activity assay | AChE enzymatic activity | Evaluate inhibitors and mutations |
| Radioligand binding | Receptor density and affinity | Characterize nAChR and mAChR pharmacology |
| Slice electrophysiology with optogenetics | Circuit-specific cholinergic effects | Map cholinergic modulation of excitatory transmission |
Electrophysiology
Patch-clamp and extracellular recordings measure postsynaptic currents and membrane potential changes evoked by ACh release, allowing quantification of cholinergic transmission strength and modulation. These methods are central to studying GO:0007271 in brain slices and cultured neurons.
Imaging of synaptic vesicles and receptors
Fluorescent labeling of synaptic vesicles, VAChT, and ACh receptors enables live imaging of release sites and receptor clustering. Super-resolution and confocal microscopy reveal nanoscale organization of cholinergic synapses.
Genetic perturbation with CRISPR
CRISPR-Cas9 knockout, point mutation, knock-in, and overexpression models allow causal testing of cholinergic genes in cell lines and animals. These approaches can be combined with electrophysiology and imaging to link genotype to synaptic phenotype.
Biochemical and pharmacological assays
ACh quantification by mass spectrometry, cholinesterase activity assays, and radioligand binding measure key steps of cholinergic transmission. Pharmacological agents such as cholinesterase inhibitors and receptor agonists/antagonists probe pathway function.
How CRISPR Can Be Used to Study GO:0007271 synaptic transmission, cholinergic
Knockout
CRISPR knockout of cholinergic genes such as CHAT, SLC18A3, or CHRNA7 in cell lines and neurons can abolish ACh synthesis, packaging, or receptor function, providing causal evidence for their roles in GO:0007271. Knockout models are also used to validate drug targets and to study compensatory mechanisms.
Point Mutation
Point mutations that mimic human disease variants, for example in CHRNE or ACHE, can be introduced with CRISPR base editing or homology-directed repair to study their effects on receptor function and synaptic transmission. These models help link specific residues to cholinergic dysfunction.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous loci such as SLC18A3 or CHRM1 allows real-time tracking of protein localization and dynamics at cholinergic synapses. Disease-relevant knock-in mutations can also be generated to model congenital myasthenic syndromes.
Overexpression
CRISPR activation or transgenic overexpression of genes like CASK or FARP1 can enhance cholinergic transmission and test sufficiency in synaptic assembly. Overexpression models are useful for gain-of-function studies and for screening modulators of cholinergic signaling.
How EDITGENE Supports synaptic transmission, cholinergic Research
Researchers studying synaptic transmission, cholinergic-related genes often need to determine whether a candidate gene is causally involved in ACh release, receptor activation, or downstream signaling. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell and animal models, enabling rigorous functional dissection of GO:0007271.
Contact EDITGENE today to design your custom CRISPR model for synaptic transmission, cholinergic research.
Frequently Asked Questions About synaptic transmission, cholinergic
What is synaptic transmission, cholinergic (GO:0007271)?
It is the biological process in which acetylcholine is released from a presynapse, activates postsynaptic receptors, and changes the postsynaptic membrane potential and ionic composition.
What genes are involved in cholinergic synaptic transmission?
Key genes include CHAT, SLC18A3 (VAChT), ACHE, CHRNA1-10, CHRNB1-4, CHRND, CHRNE, CHRM1-5, CASK, and FARP1.
How is acetylcholine released at cholinergic synapses?
Action potentials trigger calcium influx, which causes synaptic vesicles to fuse with the presynaptic membrane and release ACh into the cleft.
What receptors mediate cholinergic transmission?
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels, while muscarinic receptors (mAChRs) are G-protein-coupled receptors.
How is cholinergic transmission terminated?
Acetylcholinesterase (AChE) hydrolyzes acetylcholine into choline and acetate, stopping the signal.
What diseases involve cholinergic transmission?
Myasthenia gravis, congenital myasthenic syndromes, Alzheimer disease, Parkinson disease, and epilepsy have been linked to cholinergic dysfunction.
How do CASK and FARP regulate cholinergic transmission?
CASK and FARP localize post-synaptic ACh receptors and promote efficient cholinergic transmission.
Can cholinergic transmission be modulated by hormones?
Yes, ovariectomy reduces cholinergic modulation of excitatory synaptic transmission in the rat entorhinal cortex, indicating estrogen regulation.
What methods are used to study cholinergic transmission?
Patch-clamp electrophysiology, fluorescence imaging, CRISPR perturbation, mass spectrometry, and pharmacological assays are commonly used.
How can CRISPR help study cholinergic genes?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of cholinergic genes in cells and animals.
Conclusion
GO:0007271 synaptic transmission, cholinergic is a central biological process that underlies motor control, autonomic function, and higher cognitive processes. Its molecular machinery, from ChAT and VAChT to nicotinic and muscarinic receptors, is well defined and experimentally accessible. Dysregulation of cholinergic transmission contributes to myasthenia gravis, Alzheimer disease, Parkinson disease, and epilepsy, making it a key target for research and therapeutic development. CRISPR-based models provide powerful tools to dissect the causal roles of cholinergic genes and to accelerate discovery in this field.
References
- 1. Kramer PF et al.. 2022. Synaptic-like axo-axonal transmission from striatal cholinergic interneurons onto dopaminergic fibers.. Neuron 110(18):2949-2960.e4 PMID: 35931070
- 2. Batallán Burrowes AA et al.. 2022. Ovariectomy reduces cholinergic modulation of excitatory synaptic transmission in the rat entorhinal cortex.. PLoS One 17(8):e0271131 PMID: 35939438
- 3. Prado MAM et al.. 2017. Preface: Cholinergic Mechanisms.. J Neurochem 142 Suppl 2:3-6 PMID: 28791707
- 4. Yang D et al.. 2021. Cholinergic and Adenosinergic Modulation of Synaptic Release.. Neuroscience 456:114-130 PMID: 32540364
- 5. Li L et al.. 2022. CASK and FARP localize two classes of post-synaptic ACh receptors thereby promoting cholinergic transmission.. PLoS Genet 18(10):e1010211 PMID: 36279278
- 6. Glasgow SD et al.. 2012. Cholinergic suppression of excitatory synaptic transmission in layers II/III of the parasubiculum.. Neuroscience 201:1-11 PMID: 22138154
- 8. Vogt KE et al.. 2001. Cholinergic modulation of excitatory synaptic transmission in the CA3 area of the hippocampus.. J Neurosci 21(1):75-83 PMID: 11150322
